Biotechnology sector-related exchange traded funds are making a swift rebound as a spate of dealing making and new drug approvals helped reinvigorate the segment. For instance, the SPDR S&P Biotech ETF (XBI), which follows a more equal-weight indexing methodology that provides greater emphasis on mid-sized companies, increased 41.4% from its May lows while the iShares Biotechnology [...] The post Biotech ETFs Are on the Mend appeared first on ETF Trends .